Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OVULEN-21 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin oral contraceptive; inhibits gonadotropin release, suppressing ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial development.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (ethinyl estradiol 0.05 mg and norethindrone 1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Ethinyl estradiol: 13-27 hours (mean ~17 hours); norethindrone: 5-14 hours (mean ~8 hours); terminal half-life supports once-daily dosing.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Hepatic via CYP3A4; ethinyl estradiol undergoes oxidation and conjugation; ethynodiol diacetate is metabolized to norethindrone.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal: 50-60% as metabolites; fecal: 30-40% as conjugates; biliary excretion significant.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 80-85% bound to albumin and SHBG.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Ethinyl estradiol: 2.5-4 L/kg; norethindrone: 2.3-3.4 L/kg; indicates extensive tissue distribution.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: ethinyl estradiol 38-48%; norethindrone 64-70% (first-pass metabolism reduces bioavailability).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for renal impairment; use with caution in patients with impaired renal function.
No data available for fictional drug ALYACEN 777.
Contraindicated in patients with hepatic impairment (Child-Pugh class B or C); use not recommended.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche.
No data available for fictional drug ALYACEN 777.
Not indicated for use after menopause.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular side effects from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thromboembolic disorders; hypertension; gallbladder disease; hepatic neoplasia; glucose intolerance; blood pressure monitoring recommended; discontinue if jaundice or visual disturbances occur.
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected breast cancer; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; pregnancy; liver tumors or acute liver disease; hypersensitivity to components; smoking in women over 35.
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No significant food interactions. Grapefruit juice may increase estrogen levels; avoid excessive consumption. Maintain consistent dietary habits as high-fat meals may affect absorption.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
First trimester: Increased risk of neural tube defects, congenital heart defects, and limb reduction defects. Second and third trimesters: Potential for feminization of male fetus, vaginal adenosis, and cervical ectropion. Also associated with increased risk of miscarriage and stillbirth.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excreted in breast milk. M/P ratio not established. Reduces milk production and quality. Use caution in nursing mothers; consider alternative contraception.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Contraindicated in pregnancy. No dose adjustments applicable as use is not recommended during pregnancy.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
Ovulen-21 is a combination oral contraceptive containing ethynodiol diacetate and ethinyl estradiol. It carries an increased risk of thromboembolism, especially in smokers over 35. Prescribe with caution in patients with hypertension, migraine with aura, or history of DVT. Advise consistent timing to maintain efficacy. Consider alternative contraception in patients taking enzyme-inducing antiepileptics or rifampin.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one pill daily at the same time for 21 days, then 7 days off.,Use backup contraception if you miss a dose or start late.,Report severe headaches, chest pain, leg swelling, or vision changes immediately.,Do not smoke while taking this medication, especially if over 35 years old.,May cause nausea, breast tenderness, or breakthrough bleeding, especially in first cycles.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OVULEN-21 vs ALYACEN 777, answered by our medical review team.
OVULEN-21 is a Oral Contraceptive that works by Combination estrogen-progestin oral contraceptive; inhibits gonadotropin release, suppressing ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial development.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OVULEN-21 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OVULEN-21 is: One tablet (ethinyl estradiol 0.05 mg and norethindrone 1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OVULEN-21 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OVULEN-21 is classified as Category C. First trimester: Increased risk of neural tube defects, congenital heart defects, and limb reduction defects. Second and third trimesters: Potential for feminization of male fetus,. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.